Marrazzo Jeffrey D 4

What Happened

• Jeffrey D. Marrazzo, a director of Prime Medicine, was granted a derivative award (an option) covering 75,000 shares on June 5, 2026. The reported acquisition price is $0.00 (grant of a derivative security). This is an award/grant to a director rather than an open‑market buy or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (timely within SEC reporting window).
• Transaction type: A = Award/Grant (derivative security). Considered an acquisition of a derivative (option) covering 75,000 shares at $0.00 on the grant date.
• Shares owned after transaction: not specified in the public filing.
• Footnote: The option vests in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the reporting person’s continuous service through such vesting date.
• No indication in the filing of any immediate sale, tax withholding, 10b5-1 plan, or other special conditions.

Context

• This is a typical director equity grant meant to align interests with shareholders; it’s an award rather than the director purchasing stock with personal funds. Derivative grants signal potential future ownership if vesting and any exercise conditions are met, but do not represent current share purchases.